POPULARITY
Hosted by larry goldstein
3 episodes with larry goldstein
3 episodes with larry goldstein
4 episodes with larry goldstein
3 episodes with larry goldstein
3 episodes with larry goldstein
2 episodes with larry goldstein
3 episodes with larry goldstein
3 episodes with larry goldstein
Parneet Grewal discusses how to negotiate with your department chair- where to start, what to consider, how to approach it- with Drs. Gary Gilkeson, Associate Dean for Faculty Affairs and Faculty Development at MUSC, Helmi Lutsep, Professor and Interim Chair of Neurology at Oregon Health and Sciences University, and Larry Goldstein, Chair of Neurology at University of Kentucky.
Hello everyone, and welcome to the Coaching & Consulting Insights Series on the Success InSight Podcast.The Coaching & Consulting Insights series introduces you to coaches and consultants that work with leaders, entrepreneurs, and business owners to create their best life and achieve and perform at their full potential.Our guest today is Larry GoldsteinLarry is the author of Make Me An Offer: A Guidebook for Small Business Buyers and Sellers, and he is a Business Broker at First Choice Business Brokers Las Vegas.InSight2GoWhen I owned my business, I really learned the concept. Of Trusted Advisors, and whether a person is looking to sell their business or buy a business, to do it themselves is almost a fool's undertaking. I've got to say, I used an organization. I participated in their training and their mentorship here in Las Vegas, called, SCORE, which is a nonprofit that is associated with the Small Business Administration.And that began my learning process. At that same time when I really started to narrow in, I brought my wealth manager and his expertise into the process. And when I was looking at businesses, I engaged the services of a business attorney because I was being handed not so much concerned about non-disclosures, but I was starting to be handed contracts and other things that I knew I was going to have to deal with.And so the insight to go, that I would tell anybody entering or trying to exit a business, is to form your team of trusted advisors. They don't necessarily have to be on a fee basis. There are industry organizations of people with experience who have been through the buying or the selling and acquiring other businesses.So whether it's people in the construction industry, people in the health industry, there are in every single city, there are industry organizations and business organizations. Go, join participate, listen to the speakers, ask questions, do your reading, and form your own group of trusted advisors. These people be invaluable to you as you go through the process.To learn more about Larry and his work, visit his website at https://bizbrokernevada.comYou can also visit Larry on the following social sites:LinkedInFacebookYouTubeTo learn more about SCORE, the largest network of free volunteer small business mentors in the nation, visit their website at https://www.score.org/. No matter what stage your business is at SCORE has a mentor for you. Easily request a mentor to help you start, grow, or transition your business today.Success InSight is a production of Fox Coaching, Inc.
Larry Goldstein has been what he calls a Main Street Business Broker for many years and he has helped sell many businesses, and he has seen many of them fail. Learn what things you can do to make a stronger business in this episode! 3 Key Takeaways How a crisis should affect your businessThe three pitfalls when buying a businessHow having a good exit strategy is the key to a successful businessResourcesWebsite - fcbb.com
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Stem cell research is changing the way Alzheimer's disease is diagnosed and treated. Larry Goldstein, PhD and Doug Galasko, MD join Alysson Muotri, PhD to share the latest findings and what the future may hold. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36805]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Lawrence S.B. Goldstein, PhD discusses his career in science and his work to understand the molecular basis of neuronal defects in Alzheimer's Disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36338]
Have you considered selling your business? Do you know what your business is worth? I look forward to working with you to plan the eventual sale or purchase of your business. Using a proprietary valuation process to determine the market value of your business, you will have a starting point on the path to executing your exit plan. I am a Las Vegas, Nevada-based business broker whose expertise includes business valuation, complex negotiations, and multi-channel marketing. I successfully grew and sold my own business, providing a unique perspective of how buying and selling a business really works. https://www.linkedin.com/in/larrygoldstein1/
ThinkTech is a Hawaii 501(c)(3) nonprofit. Please support us by making a donation. http://www.thinktechhawaii.com Will the OPEC oil production agreement solve the problem. Lou Pugliaresi and Larry Goldstein wrote an article for Real Clear Energy arguing that in lieu of oil quotas and import fees we really just need to get America to get back to work. Lou Pugliaresi will discuss and explain the article, and give us an update and effect of the recent OPEC oil production agreement. The host for this episode is Jay Fidell. The guest for this episode is Lou Pugliaresi.
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Health and Medicine] [Humanities] [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Show ID: 35245]
The study of brain organoids is leading to a better understanding of human development and potential therapies for neurological disorders. Yet when people hear the phrase "brain in a dish" it instantly brings to mind the stuff of science fiction - labs full of sentient brains thinking and plotting. Alysson Muotri explains why these organoids should not called "brains in a dish" and how they are being used to explain human processes previously inaccessible to study. While underscoring scientific value of these organoids, he also raises the question of what ethical questions demand an answer as the technology improves. Series: "Stem Cell Channel" [Health and Medicine] [Humanities] [Show ID: 35245]
This week on NACUBO In Brief, we bring you part three of our four-part series dissecting one of higher education’s biggest challenges: financial modeling and forecasting in the face of great uncertainty. In our last episode, we discussed how institutions can build a forecasting and scenario planning process that is grounded in budgeting. This week, we take scenario planning to the next level with examples of sophisticated applications that can help institutions see around corners. NACUBO’s senior director of accounting policy Sue Menditto invites two experts in for the conversation; Larry Goldstein, President of Campus Strategies and author of College and University Budgeting, and Brett Matteo, managing director of The PFM Group and president of Synario software (formerly known as Whitebirch).
This week on NACUBO In Brief, we bring you part four of our four-part series dissecting one of higher education’s biggest challenges: financial modeling and forecasting in the face of great uncertainty. In our last episode, we presented sophisticated applications of scenario planning that can help institutions take their budgeting and forecasting models to the next level. In our final episode, our guests offer a survey of their experience working with campuses that have experience in using these more advanced analytical tools. NACUBO’s senior director of accounting policy Sue Menditto invites two experts in for the conversation; Larry Goldstein, President of Campus Strategies and author of College and University Budgeting, and Brett Matteo, managing director of The PFM Group and president of Synario software (formerly known as Whitebirch).
Unstable future revenues. Ballooning costs. Shifting demographics. For some, the challenges facing our institutions are no longer posing questions about what our schools will look like in the future, but whether our schools have a future at all. Even the most fortunate are concerned that there won’t be sufficient resources to sustain excellence — much less fund new ambitions. This week on NACUBO In Brief, we bring you part one of a four-part series dissecting one of higher education’s biggest challenges: financial modeling and forecasting in the face of great uncertainty. NACUBO’s senior director of accounting policy Sue Menditto invites two experts in for the conversation; Larry Goldstein, President of Campus Strategies and author of College and University Budgeting, and Brett Matteo, managing director of The PFM Group and president of Synario software (formerly known as Whitebirch).
This week on NACUBO In Brief, we bring you part two of our four-part series dissecting one of higher education’s biggest challenges: financial modeling and forecasting in the face of great uncertainty. In our last episode, we made the case for the value of forecasting. This week, we dive deeper, discussing the process of forecasting with illustrations of how institutions can build a forecasting and scenario planning process that is grounded in budgeting. NACUBO’s senior director of accounting policy Sue Menditto invites two experts in for the conversation; Larry Goldstein, President of Campus Strategies and author of College and University Budgeting, and Brett Matteo, managing director of The PFM Group and president of Synario software (formerly known as Whitebirch).
There are drug trial failures. And there are drug trial failures. The recent move by drug giant Biogen to halt their Alzheimer’s drug has not only been a setback for the company—their stock fell precipitously on the news—it’s also been a major setback for the whole research community focused on this disease. The Biogen trial was one of the last of the major drug companies with high hopes for a significant therapeutic step forward for the neurodegenerative disease. The last five years has seen one big pharma players after another throw in the towel.
Imagine Mark Twain’s iconic ne’er-do-well as the high school counselor who launched your career. LA native and Emeritus Professor Larry Goldstein shares some of his poetry about Los Angeles and tells the story of how child actor Tommy Kelly (who once played Tom Sawyer in the movies) set him on a writing and teaching career that would have made Aunt Polly proud. Read full story at Michigan Today More on Larry Goldstein Faculty Contact Poetry Los Angeles: Reading the Essential Poems of the City
1) Influence of sodium consumption and associated knowledge on post-stroke hypertension in Uganda2) e-Pearl topic: Transient cerebral arteriopathy3) Topic of the month: Neurologic prognosis following cardiac arrestThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Larry Goldstein about his paper on the influence of sodium consumption and its associated knowledge on post-stroke patients with and without a history of hypertension in Uganda. Dr. Adam Numis is reading our e-Pearl of the week about transient cerebral arteriopathy. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the ancillary testing that is done in patients with cardiac arrest.DISCLOSURES: Dr. Goldstein serves as an editorial board member of Neurology®, Emergency Medicine, Cardiology Today and Stroke; serves as an Associate Editor for Cerebrovascular Diseases; serves on the scientific advisory board for Daichi Sanyo, Merz, Roche and Pfizer Inc; is a consultant for Artemida, Nestle and Stroke Hospitalization in Elderly with Medicare; receives honoraria from serving on the scientific advisory board of Pfizer Inc; receives royalties from the publication of the books: Screening for Asymptomatic Carotid Stenosis, Use and Utility of Stroke Scales and Grading Sysytems and Henry Stewart Talks, Secondary Stroke Prevention; receives research support from Stroke Hospitalization in Elderly with Medicare and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.
Scott and Heather learn about CRISPR/Cas9, the hot new technique for editing genes. They talk to John Steele, a postdoctoral researcher in Larry Goldstein’s lab in the UC San Diego School of... A podcast about science and discovery at UC San Diego Health. In each episode, we bring you the story of one project, one discovery or one scientist.
Stem cells, cells that have the ability to develop into different cell types, hold great promise for the treatment and prevention of Alzheimer’s disease. Dr. Larry Goldstein – Distinguished Professor in the Department of Cellular and Molecular Medicine at University of California, San Diego; Director of the UC San Diego Stem Cell Program; Director of the Sanford Stem Cell Clinical Center; and Scientific Director of the Sanford Consortium for Regenerative Medicine – joined us for November’s Alzheimer’s Talks. He described some of the groundbreaking research being done and offered a glimpse of potential future therapies and treatments for Alzheimer’s disease using stem cell technology.Support the show (https://www.usagainstalzheimers.org/ways-donate)
Guests: Larry Goldstein, PhD, Director, UCSD Stem Cell Program Bio and Contact Info Listen (3:16) Where are we at today with stem cell research? Listen (5:14) One step beyond animal models
Travis from The Beer Amigos speaks with Rick Sobotka of Great South Bay Brewery; Larry Goldstein of Spider Bite Brewing Company; and Bob Stacey of Palm Breweries at the fifth annual International Great Beer Expo on November 17, 2012; Niko Krommydas of The Beer Amigo interviews Niko Krommydas of Super Neat Beer Adventure, Yes!!; The Beer Amigos and Niko Krommydas sing their "Reasons To Drink Long Island Brews" song; and much more! *** The Beer Amigos is the premier Long Island craft beer podcast. It stars Travis Johnides and Michael Howland, two advocates and lovers of Long Island craft beer. For more information, please visit: http://www.thebeeramigos.com ***
It’s a crisp fall evening in Brooklyn, and Jimmy Carbone’s packed the house for another installment of Beer Sessions Radio. Tonight, Jimmy’s joined by Justin Robertson, Brian Strumke, and a wealth of other awesome beer guests! In the studio is Rev. David Ciancio, owner of beer and bourbon bar, Idle Hands. Also, Larry Goldstein and Paul Kretzer from Spider Bite Brewing Co. bring by two awesome brews- the Boris Russian Imperial Stout and the Eight-Legged RyePA. Jimmy Ludwig from The Happy Hour Guys is in the house talking about a potential network television debut for his show. Hear the cast talk about the San Diego beer scene, their favorite beer cities, and the holiday beer phenomenon. This episode has been brought to you by GreatBrewers.com. “Owning a beer bar is a little egotistical. You’re tasting what I like, and I’ll admit it.” [25:20] — Rev. David Ciancio on Beer Sessions Radio “There are so many traditional styles of beer that fit the winter and fall, but hardly anybody is making a good porter, which is what I want to drink now.” [33:00] — Jimmy Carbone on Beer Sessions Radio
1) Functional psychogenic symptoms and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Michael Sharpe about his paper on guided self-help for functional (psychogenic) symptoms. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Melkersson-Rosenthal syndrome. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 2. Over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, Mark Eckman and Tom Brott about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Sharpe, Burns, Fugate, Kissela, Sacco and Goldstein.Dr. Sharpe serves as an Associate Editor for the Journal of Psychosomatic Research and on the editorial boards of General Hospital Psychiatry, Psychological Medicine, and Psychosomatics; serves as an independent medical advisor to AEGON Insurance; receives publishing royalties from Oxford University Press, Wiley-Blackwell and Churchill Livingstone and serves on a DSM5 work group for the American Psychiatric Association; is a member of Council of the Academy of Psychosomatic Medicine and receives research support from the Medical Research Council UK and Cancer Research UK.Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).
1) Duchenne muscular dystrophy and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Diana Escolar about her paper on weekend versus daily prednisone in Duchenne muscular dystrophy. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Guillain-Barre-like syndrome with thallium poisoning. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 1. Next week you will hear part 2 and over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Escolar, Fugate, Kissela, Sacco and Goldstein.Dr. Escolar serves on a scientific advisory board for the NIH/NINDS; serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Athena Diagnostics, Inc.; has received speaker honoraria from Kennedy Krieger Institute and Acceleron Pharma; serves as a consultant for Gerson Lheman Group (GLC), Acceleron Pharma, and Medacorp; and receives research support from the NIH, the Muscular Dystrophy Association, and the Foundation to Erradicate Duchenne (FED).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).
© 2020-2025 Ivy Podcast Discovery LLC
